Loading
steve-bod

Steve Basta has served as Chief Executive Officer of Menlo Therapeutics, Inc. since September 2015.  Prior to joining Menlo Therapeutics, Mr. Basta served from 2011 to 2015 as CEO of AlterG, Inc. a privately held rehabilitation company which commercializes the AlterG Anti-Gravity Treadmill.

From 2002 through 2011, Mr. Basta served as CEO of BioForm Medical, Inc. and its successor, Merz Aesthetics, Inc. Mr. Basta led BioForm’s growth from initial product launch to $80 million in annual revenues at the time of it’s acquisition by Merz, and subsequently led Merz Aesthetics through multiple product launches managing a global business unit which was the #3 worldwide injectable aesthetics business.

Prior to Bioform Medical, Mr. Basta served as President and CEO of Gliatech, Inc., a medical device company, VP Business Development and Chief Financial Officer of Creative BioMolecules, Inc., a protein therapy and drug device combination products company, and Executive Director of Product Development for The Immune Response Corporation, a biotechnology company.

Mr. Basta also served for two years as an associate with the investment banking firm, Dillon, Read & Co. Inc. Mr. Basta received his MBA from the Kellogg Graduate School of Business at Northwestern University, and his bachelor’s degree in biomedical engineering from The Johns Hopkins University.

Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Aclaris Therapeutics (NASDAQ: ACRS), Ascendis Pharma A/S (NASDAQ: ASND), ProNAi Therapeutics (NASDAQ: DNAI), Carbylan Therapeutics (NASDAQ: CBYL), AirXpanders (ASX: AXP), and several private companies.

He was an investor in Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Entrepreneurship Conference. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.

Albert received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience.

David is Chief Executive Officer of Velocity Pharmaceutical Development and Managing Director of Presidio Partners. As CEO of Velocity Pharmaceutical Development (VPD), Dr. Collier is pioneering a new business model for the development of promising drug candidates. VPD acquires the rights to individual therapeutic drug candidates from biotechnology companies, academia, and pharmaceutical companies, and invests in their development through clinical proof-of-concept (generally phase 2). Following proof-of-concept, VPD seeks to sell each drug asset to a major pharmaceutical company. VPD is structured as a holding company, owning a portfolio of virtual companies, each of which develops a single drug candidate, all managed by a single expert team. This development team included several highly experienced former Chief Medical Officers from the biotechnology industry.

Dr. Collier joined Presidio Partners in 2001 to focus on investments in biotechnology companies developing drugs through clinical trials across many different therapeutic areas. Examples include Ardelyx (minimally-absorbed drugs acting on the GI tract), Bayhill Therapeutics (autoimmune disorders), Arcion Therapeutics (neuropathic pain), Altus Pharmaceuticals (malabsorption in cystic fibrosis) and Sorbent Therapeutics (congestive heart failure). Dr. Collier currently serves as Chairman of the Board of two Presidio Partners drug development portfolio companies and as a board member of three others. Before joining Presidio Partners, David was a Managing Director at Burrill & Co., a private merchant bank focused exclusively on life science companies, where he played a leading role in the management of the company’s life science venture capital funds. Earlier in his career, David was Assistant Vice President at First Options of Chicago where he directed a group of traders and managed a large portfolio of futures and options.

Dr. Collier holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School, and a B.A. in Physics from Wesleyan University.

Mr. Creecy is Chief Executive Officer and a Director of Remeditex Ventures after serving as President and Chief Executive Officer of Hunt Petroleum Corporation.

Prior to that, Mr. Creecy served as Chief Operating Officer of Hodges Company, Inc. Mr. Creecy is a Graduate of Texas Tech University with a Bachelor’s Degree in Accounting and holds a Master of Science Degree in Tax from North Texas State University (Now the University of North Texas).

Mr. Creecy is a member of both the Dallas Assembly and the Dallas Citizens Council, civic organizations comprised of business leaders in Dallas.

Ted Ebel serves as Chief Business Officer at Colorescience. Mr. Ebel has 20 years of experience in the health, wellness and consumer products industries. Prior to Colorescience, Mr. Ebel was Senior Vice President of Corporate Development for SkinMedica, Inc. having responsibility for mergers and acquisitions, licensing, intellectual property management, market research and establishing the company’s international operations.

Earlier in his career, Mr. Ebel served as the Executive Director of Corporate Development at CancerVax Corporation, a biotechnology company focused on cancer immunotherapy, and as the Vice President of Strategic Ventures for MP3.com, a publicly traded internet and entertainment company. In addition, Mr. Ebel held positions in marketing and corporate development at Amgen, Inc. and began his career as a consultant in the health care practice of the management consulting firm Arthur D. Little. Mr. Ebel received his Bachelor of Science, Magna Cum Laude, from Duke University, and his MBA from the Wharton School at the University of Pennsylvania.

Ketan Patel has worked in healthcare sector as an investor, consultant, and physician. Prior to joining F-Prime Capital in 2007, Dr. Patel was an engagement manager in the corporate consulting division of Leerink Swann & Company. While at Leerink, he advised biopharmaceutical and medical device companies on brand strategy, clinical development plans, and business development activities. Dr. Patel served as a physician at the VA Boston Healthcare System and at Weill Cornell Medical Center-New York Presbyterian Hospital and Memorial-Sloan Kettering Cancer Center where he completed his internal medicine training.

Dr. Patel focuses on investing in therapeutics and medical device companies and has served as a director or board observer of Aclaris Therapeutics, Acorn Cardiovascular, Amphora Medical, Bioconnect Systems, Ivenix, Laurus Labs, Medwell Ventures, NextWave Pharmaceuticals, Trivitron Healthcare, Vicept Therapeutics, and Xcyton Diagnostics.

Dr. Patel is a graduate of Tufts University School of Medicine, where he received both his MD and MBA as part of that institution’s Healthcare Management Program and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his undergraduate studies in biology and economics with highest honors at Rutgers University.

Aaron Royston, M.D., M.B.A. is a Partner at venBio with a background in life science investing, healthcare strategy, and as an entrepreneur. Dr. Royston led venBio’s investments into Apellis Pharmaceuticals, Nabriva Therapeutics (Nasdaq: NBRV), and Impel NeuroPharma.

Prior to joining venBio, Dr. Royston worked for Vivo Capital, a global life science venture capital firm. While at Vivo, he was involved in the firm’s investments in Biotie Therapies (Nasdaq: BITI, acquired by Acorda), RegenxBio (Nasdaq: RGNX), and Crinetics Pharmaceuticals, among others. Previously, he worked at Bain & Company, where he advised biotechnology companies on a broad range of strategic and operational issues. Earlier in his career, Dr. Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences.

Dr. Royston received his B.S. in biological sciences from Duke University, and his M.D. and M.B.A. degrees from the University of Pennsylvania. In 2010, Dr. Royston was recognized by the Obama Administration as a Champion of Change for his work in Technology and Innovation. Dr. Royston is active in the community and currently serves on the board of SFBWS, an environmental non-profit authorized by Congress to support the education and research of the U.S. Fish and Wildlife Service.

scott

Dr. Scott Whitcup is founder and CEO of Akrivista and Whitecap Biosciences, two companies focused on the development and commercialization of novel therapies in ophthalmology and dermatology.

Previously, Dr. Whitcup was the Executive Vice President, R&D and Chief Scientific Officer at Allergan where he lead the discovery and global development of both pharmaceutical products and medical devices in therapeutic areas including ophthalmology, CNS, urology, dermatology, medical aesthetics, and surgical obesity. Key product approvals included Botox® for chronic migraine, upper limb spasticity, and crow’s feet lines; Restasis® for dry eye; Alphagan® Lumigan®, and Combigan® for glaucoma; Ozurdex® for diabetic macular edema; and Juvederm Voluma® for facial aesthetics. Dr. Whitcup was in charge of the global medical affairs organization and involved in the commercial launch of more than a dozen pharmaceutical and medical device products globally. He also built the technology assessment group to support Allergan’s business development and M&A activities.

Before Allergan, Dr. Whitcup was the Clinical Director at the National Eye Institute at the NIH, where he led its intramural clinical research program, headed an immunology lab in the Clinical Branch, and Chaired the NIH Medical Executive Committee. Dr. Whitcup has a B.A. in Neurobiology and Behavior from Cornell University and an M.D from Cornell University Medical College.

He has completed a residency in Internal Medicine at UCLA, a residency in Ophthalmology at Harvard Medical School-Massachusetts Eye & Ear Infirmary, and a fellowship in Uveitis and Ocular Immunology at the National Eye Institute, National Institutes of Health. He is a Diplomate of both the American Board of Internal Medicine and the American Board of Ophthalmology, a licensed M.D. in CA, and is on the Clinical Faculty of the Department of Ophthalmology, at the Jules Stein Eye Institute, David Geffen School of Medicine at UCLA. Dr. Whitcup has published more than 250 scientific articles and co-authored a leading textbook on uveitis and ocular immunology.

He has 17 issued and 20 pending US patents and over 300 issued and pending international patents. Dr. Whitcup serves on the Board of Semnur Pharmaceuticals and has served on the Boards of Avanir Pharmaceuticals and Questcor Pharmaceuticals.

Science behind serlopitant